Discovery Service Collaboration Sanofi to Invest 250 Million Euro for a Collaboration with Evotec
Evotec will provide a broad range of long-term drug discovery services to Sanofi. This agreement is centred on the core small-molecule discovery platforms in Toulouse for the period of the contract over the next five years. The total deal value amounts 250 million Euro.
Hamburg/Germany - Sanofi will outsource some parts of its research activities and employ Evotec as a partner. The five-year agreement includes several initiatives:
- Major pipeline-building initiative with focus on oncology;
- Evotec acquires Sanofi's scientific operations and related employees at Toulouse site;
- Creation of Evotec's European compound management centre ;
- Sanofi and Evotec offering joint small molecule libraries to biotech and other Pharma players for hit discovery.
Capacity and Capability Expansion
Evotec will expand its industry-leading capabilities in drug discovery by integrating a state-of-the-art facility of approx. 20 000 m2 and more than 200 highly qualified and experienced employees in Toulouse, France. Evotec will integrate the Toulouse capacities into its global drug discovery infrastructure and offering. The expanded capabilities will serve to support collaborative research in drug discovery from screening to identification of pre-clinical candidates with Evotec's Pharma, biotech, venture capital and academic partners.
Furthermore Evotec will provide a broad range of long-term drug discovery services to Sanofi. This agreement is centred on the core small-molecule discovery platforms in Toulouse for the period of the contract over the next five years. In addition, Evotec will assume management of Sanofi's global screening compound library.